We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Begins Rolling Review of Moderna’s mRNA Vaccine Candidate
EMA Begins Rolling Review of Moderna’s mRNA Vaccine Candidate
The European Medicines Agency (EMA) has launched a rolling review of Moderna’s vaccine candidate mRNA-1273, on the heels of the Cambridge, Mass., drugmaker’s announcement that the vaccine demonstrated 94.5 percent efficacy in early results from a phase 3 trial.